Why the study?
Do early changes in plasma NT-pro-BNP levels predict clinical benefit and progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib?
Population
36 patients with metastatic clear-cell renal carcinoma treated with sunitinib
Comparison
Monitoring of plasma NT-pro-BNP levels during… vs Patients with <1.5 fold increase versus >1.5…
Design
Cohort
Authors
Loading...
NT-pro-BNP changes may stratify sunitinib response in metastatic RCC; hypothesis-generating and requires prospective validation before clinical use.
Do early changes in plasma NT-pro-BNP levels predict clinical benefit and progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib?
Early increases in plasma NT-pro-BNP levels strongly correlate with disease progression and shorter progression-free survival in patients receiving sunitinib for metastatic renal cell carcinoma.
Papazisis et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: